ArticleJournal of clinical microbiology2023
Diagnostic Performance and Clinical Impact of Metagenomic Next-Generation Sequencing for Pediatric Infectious Diseases.
Article in Journal of clinical microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed.
- Utility of Metagenomic Next-Generation Sequencing in Identifying Anaerobic Pathogens in a Pediatric Brain Abscess Secondary to Sinusitis: A Case Report.Clinical case reports · 2026Article
- Clinical, immunological, and molecular characteristics of severe combined immune deficiency in China.Human genetics · 2026Article
- Clinical utility of metagenomic next-generation sequencing in precision diagnosis of infectious diseases: a retrospective study based on bronchoalveolar lavage fluid, blood, and cerebrospinal fluid.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- [Application of metagenomic next-generation sequencing in the pathogen spectrum analysis of suspected infections in neonatal blood and cerebrospinal fluid].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2026Article
- A novel diagnostic and treatment paradigm for Streptococcus pasteureus infection in neonates: a case study.BMC pediatrics · 2026Article
- Next-generation sequencing of cell-free microbial DNA in blood samples of critically ill children: a single-center experience.Molecular and cellular pediatrics · 2026Article
- Impact of Metagenomic Next-Generation Sequencing on Antibiotic Management in Pediatric Patients.Medicina (Kaunas, Lithuania) · 2026Article
- The clinical utility of metagenomic next-generation sequencing in the management of fever in patients with hematological disorders.Nagoya journal of medical science · 2026Article
- Cerebrospinal Fluid Metagenomic Next-Generation Sequencing in Pediatric Central Nervous System Infection: Clinical Experience and Diagnostic Stewardship Strategies.Open forum infectious diseases · 2026Article
- Complementary mNGS and traditional testing for bloodstream infections.Open medicine (Warsaw, Poland) · 2026Review
- Clinical application of metagenomic next-generation sequencing (mNGS) in children with suspected bloodstream infection.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Application of metagenomic next-generation sequencing in children with pneumonia of unknown etiology.Frontiers in cellular and infection microbiology · 2026Article
- Clinical metagenomics for diagnosis and surveillance of viral pathogens.Nature reviews. Microbiology · 2026Review
- Unveiling Neonatal Pneumonia Microbiome by High-throughput Sequencing and Droplet Culturomics.Genomics, proteomics & bioinformatics · 2025Article
- Clinical application and impact of metagenomic next-generation sequencing for the diagnosis of infectious diseases in severely immunocompromised pediatric patients.BMC pediatrics · 2025Article
- Recent Advances in Pediatric Infectious Diseases: A Review of Diagnostic and Therapeutic Strategies.Cureus · 2025Review
- Use of metagenomic next-generation sequencing for accurate diagnosis of tuberculous pleurisy: a retrospective cohort study.Journal of thoracic disease · 2025Article
- Metagenomic next-generation sequencing for concurrent diagnosis of infections and malignancies in patients with lung lesions: a single-center prospective study.Scientific reports · 2025Article
- Epidemiological characteristics and trends in the diagnosis and treatment of fungal otitis externa in children.Translational pediatrics · 2025Article
- Fever in Children with Cancer: Pathophysiological Insights Using Blood Transcriptomics.International journal of molecular sciences · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metagenomic next-generation sequencing (mNGS) has shown promise in the diagnosis of infectious diseases in adults, while its efficacy in pediatric infections remains uncertain. We performed a retrospective analysis of 1,493 mNGS samples from pediatric patients with blood, central nervous system, and lower respiratory tract infections. The positive percent agreement (PPA) and the negative percent agreement (NPA) of mNGS were compared to conventional microbiological tests (CMT) based on clinical diagnosis. The agreement of mNGS compared to CMT, as well as the clinical impact of mNGS, were valuated. Using the clinical diagnosis as a reference, mNGS demonstrated a significantly higher overall PPA compared to CMT (53.1% [95% CI = 49.7 to 56.6%] versus 25.8% [95% CI = 22.8 to 28.9%]), while maintaining a comparable overall NPA (93.2% [95% CI = 91.3 to 95.1%] versus 97.2% [95% CI = 95.9 to 98.4%]). In septic patients under 6 years of age or with immunosuppressive status, mNGS showed a higher PPA and a comparable NPA compared to CMT. The overall PPA and NPA of mNGS compared to CMT were 75.3 and 75.0%, respectively. The majority of cases of Streptococcus pneumoniae, Streptococcus agalactiae, Mycobacterium tuberculosis complex, and Pneumocystis jirovecii infections were identified by mNGS. A positive clinical impact of 14.0% (206/1,473), a negative impact of 0.8% (11/1,473), a nonimpact of 84.7% (1,248/1,473), and an unknown impact of 0.5% (8/1,473) were observed in the mNGS results. Notably, the positive impact was greater among immunosuppressed patients than among nonimmunosuppressed individuals (67/247, 27.1% versus 139/1,226, 11.3%;
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.